Logo image of BTAI

BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis

NASDAQ:BTAI - Nasdaq - US09075P2048 - Common Stock - Currency: USD

1.96  +0.12 (+6.52%)

After market: 1.89 -0.07 (-3.57%)

Fundamental Rating

1

BTAI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. BTAI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BTAI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTAI has reported negative net income.
BTAI had a negative operating cash flow in the past year.
In the past 5 years BTAI always reported negative net income.
BTAI had a negative operating cash flow in each of the past 5 years.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

BTAI has a worse Return On Assets (-103.88%) than 77.28% of its industry peers.
Industry RankSector Rank
ROA -103.88%
ROE N/A
ROIC N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BTAI has been increased compared to 1 year ago.
Compared to 5 years ago, BTAI has more shares outstanding
The debt/assets ratio for BTAI is higher compared to a year ago.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

BTAI has an Altman-Z score of -27.72. This is a bad value and indicates that BTAI is not financially healthy and even has some risk of bankruptcy.
BTAI has a Altman-Z score of -27.72. This is amonst the worse of the industry: BTAI underperforms 88.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.72
ROIC/WACCN/A
WACC7.24%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BTAI has a Current Ratio of 1.48. This is a normal value and indicates that BTAI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.48, BTAI is doing worse than 81.75% of the companies in the same industry.
A Quick Ratio of 1.45 indicates that BTAI should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.45, BTAI is not doing good in the industry: 81.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.45
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

BTAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.65%, which is quite impressive.
BTAI shows a small growth in Revenue. In the last year, the Revenue has grown by 5.35%.
EPS 1Y (TTM)83.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.22%
Revenue 1Y (TTM)5.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.13%

3.2 Future

The Earnings Per Share is expected to grow by 17.42% on average over the next years. This is quite good.
The Revenue is expected to grow by 154.27% on average over the next years. This is a very strong growth
EPS Next Y56.81%
EPS Next 2Y27.11%
EPS Next 3Y23.79%
EPS Next 5Y17.42%
Revenue Next Year-15.93%
Revenue Next 2Y81.31%
Revenue Next 3Y245.37%
Revenue Next 5Y154.27%

3.3 Evolution

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTAI. In the last year negative earnings were reported.
Also next year BTAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

BTAI's earnings are expected to grow with 23.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.11%
EPS Next 3Y23.79%

More info and screens

0

5. Dividend

5.1 Amount

BTAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (6/9/2025, 8:13:11 PM)

After market: 1.89 -0.07 (-3.57%)

1.96

+0.12 (+6.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners5.44%
Inst Owner Change-94.6%
Ins Owners1.53%
Ins Owner Change13.38%
Market Cap11.88M
Analysts74.55
Price Target30.4 (1451.02%)
Short Float %2.42%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.72%
Min EPS beat(2)45.53%
Max EPS beat(2)77.91%
EPS beat(4)4
Avg EPS beat(4)59.13%
Min EPS beat(4)42.08%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)25.09%
EPS beat(12)5
Avg EPS beat(12)11.68%
EPS beat(16)8
Avg EPS beat(16)10.75%
Revenue beat(2)0
Avg Revenue beat(2)-55.31%
Min Revenue beat(2)-61.4%
Max Revenue beat(2)-49.22%
Revenue beat(4)1
Avg Revenue beat(4)-38%
Min Revenue beat(4)-83.93%
Max Revenue beat(4)42.56%
Revenue beat(8)2
Avg Revenue beat(8)-28.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.36%
PT rev (3m)-41.95%
EPS NQ rev (1m)18.71%
EPS NQ rev (3m)42.44%
EPS NY rev (1m)44.11%
EPS NY rev (3m)43.48%
Revenue NQ rev (1m)-36.84%
Revenue NQ rev (3m)-47.83%
Revenue NY rev (1m)-25.51%
Revenue NY rev (3m)-42.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.55
EYN/A
EPS(NY)-9.98
Fwd EYN/A
FCF(TTM)-10.95
FCFYN/A
OCF(TTM)-10.95
OCFYN/A
SpS0.31
BVpS-14.88
TBVpS-14.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.45
Altman-Z -27.72
F-Score2
WACC7.24%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.22%
EPS Next Y56.81%
EPS Next 2Y27.11%
EPS Next 3Y23.79%
EPS Next 5Y17.42%
Revenue 1Y (TTM)5.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.13%
Revenue Next Year-15.93%
Revenue Next 2Y81.31%
Revenue Next 3Y245.37%
Revenue Next 5Y154.27%
EBIT growth 1Y63.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.06%
EBIT Next 3Y29.12%
EBIT Next 5Y29.91%
FCF growth 1Y57.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.26%
OCF growth 3YN/A
OCF growth 5YN/A